John Libbey Eurotext

European Journal of Dermatology

MENU

Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer Article à paraître

Illustrations

  • Figure 1
Auteurs
1 Division of Cutaneous Science, Department of Dermatology, Nihon University School of Medicine, Tokyo, Japan
2 Department of Obstetrics and Gynaecology, Nihon University School of Medicine, Tokyo, Japan

Omalizumab, a neutralizing anti-IgE antibody, is widely used for severe urticaria. However, its efficacy and safety in cancer patients with urticaria is still unknown. Here, we report a patient with ovarian cancer and intractable chronic spontaneous urticaria (CSU) which was successfully treated with omalizumab.A 49-year-old Japanese woman presented to our department with a 10-month history of repeated wheals and itching. She had a history of CSU since some years. Ovarian cancer (Stage IIIc: pT3cN0M0, [...]